Purchase this article with an account.
Michelle V Carle, Lauren Hill, Tatiana Ecoiffier, Shamika Gune; Posterior vitreous status did not impact ranibizumab treatment outcomes in HARBOR study patients with neovascular AMD. Invest. Ophthalmol. Vis. Sci. 2017;58(8):407.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
The status of the posterior vitreous (PV) may play a role in inflammatory processes and oxygenation status of the retina. Whether the PV is attached or detached may impact the effect of anti-VEGF treatment of retinal diseases and the HARBOR study dataset may inform us of any correlation between PV status and ranibizumab treatment outcomes in the setting of Neovascular AMD. We evaluated the impact of posterior vitreous (PV) status on 24-month ranibizumab (RBZ)-treatment outcomes in HARBOR study patients with neovascular AMD using a retrospective data analysis of existing OCT scans.
A retrospective analysis of OCT scan data obtained on patients during treatment in the HARBOR study was performed to determine PV status based on macular cube scans from all scheduled visits. There was no variable that directly assessed posterior vitreous detachment (PVD); the posterior hyaloid attachment/detachment was used to determine PVD. Status was categorized as: PV detached/not detectable (PVD) or attached (no PVD). If a patient had PVD once, they were considered to have PVD at all remaining visits. If a patient did not have PVD at baseline, they could switch to PVD. PVD status between three groups (PVD at baseline and persistent throughout, PVD developed during treatment, and never developed PVD) were compared using BCVA changes from baseline as well as changes in central subfield thickness during the 24 month course of treatment with ranibizumab.
There were no clinically meaningful differences between eyes with (840) or eyes without (249) PVD at baseline for mean (95% CI) changes from baseline to Month 24 in BCVA (letters; 8.3 [7.2, 9.4] vs 10.5 [8.4, 12.5], respectively) or central subfield thickness (CST, µm; -152 [-161, -143] vs -149 [-167, -131], respectively). For eyes without PVD at baseline, there were no clinically meaningful differences between eyes that did (193)/did not (56) develop PVD during the study for mean changes from baseline to Month 24 in BCVA (10.6 [8.2, 13.0] vs 10.0 [5.8, 14.3], respectively) or CST (-156 [-177, -134] vs -126 [-161, -90], respectively).
There was no relationship between PV status and BCVA or CST outcomes at Month 24 in the HARBOR study.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only